Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance. (28th January 2015)

• Record Type: Journal Article
• Authors: Qureshi, Zubair A.; Hittle, Lauren E.; O'Hara, Jessica A.; Rivera, Jesabel I.; Syed, Alveena; Shields, Ryan K.; Pasculle, Anthony W.; Ernst, Robert K.; Doi, Yohei
• Is Part Of: Clinical infectious diseases. Volume 60:Number 9(2014:Nov. 01)
• Page Start: 1295
• Page End: 1303
• Publication Date: 2015-01-28
• Subjects: Acinetobacter baumannii -- carbapenem resistance -- colistin resistance -- molecular typing -- lipid A; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/civ048
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract : Twenty patients with colistin-resistant A. baumannii were identified. Most had ventilator-associated pneumonia and all but 1 received prior colistin methansulfonate. The 30-day all-cause mortality rate was 30%. Isolates belonged to international clone II and possessed phosphoethanolamine modification of lipid A. Abstract: Background. With an increase in the use of colistin methansulfonate (CMS) to treat carbapenem-resistant Acinetobacter baumannii infections, colistin resistance is emerging. Methods. Patients with infection or colonization due to colistin-resistant A. baumannii were identified at a hospital system in Pennsylvania. Clinical data were collected from electronic medical records. Susceptibility testing, pulsed-field gel electrophoresis (PFGE), and multilocus sequence typing (MLST) were performed. To investigate the mechanism of colistin resistance, lipid A was subjected to matrix-assisted laser desorption/ionization mass spectrometry. Results. Twenty patients with colistin-resistant A. baumannii were identified. Ventilator-associated pneumonia was the most common type of infection. Nineteen patients had received intravenous and/or inhaled CMS for treatment of carbapenem-resistant, colistin-susceptible A. baumannii infection prior to identification of colistin-resistant isolates. The 30-day all-cause mortality rate was 30%. The treatment regimen for colistin-resistant A. baumannii infection associated with the lowest mortality rate was a combination of CMS, a carbapenem, and ampicillin-sulbactam. The colistin-susceptible and -resistant isolates from the same patients were highly related by PFGE, but isolates from different patients were not, suggesting evolution of resistance during CMS therapy. By MLST, all isolates belonged to the international clone II, the lineage that is epidemic worldwide. Phosphoethanolamine modification of lipid A was present in all colistin-resistant A. baumannii isolates. Conclusions. Colistin-resistant A. baumannii occurred almost exclusively among patients who had received CMS for treatment of carbapenem-resistant, colistin-susceptible A. baumannii infection. Lipid A modification by the addition of phosphoethanolamine accounted for colistin resistance. Susceptibility testing for colistin should be considered for A. baumannii identified from CMS-experienced patients.